Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2999

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler, Denis Rybin, Andrew L. Frelinger, III, Alan D. Michelson, Ke Liu, Xiufeng Gao, Jennell White, Ahmar U. Zaidi, Robert J. Charnigo, Michael U. Callaghan

Blood (2021) 137 (15): 2010–2020.

https://doi.org/10.1182/blood.2020006020

Published: 2021

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

Wally R Smith, MD, Donna k McClish, PhD, Shirley Johnson, BA, LSW, Richard Lottenberg, MD, India Sisler, MD, Daniel Sop, BS,MS, Anthony Villella, MD, Darla K Liles, MD, Elizabeth Yang, MD PhD, Ian Chen, MD

Blood (2019) 134 (Supplement_1): 2168.

https://doi.org/10.1182/blood-2019-131266

Published: 2019

Journal Articles

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Alexandra Kruse, Caroline Kruse, Nancy Potthast, Kelsey Milligan, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 2362.

https://doi.org/10.1182/blood-2019-122278

Published: 2019

Journal Articles

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Kristin A. Shimano, MD, Rachael F. Grace, MD, Carolyn M. Bennett, MDMSc, Robert J Klaassen, MD FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 2369.

https://doi.org/10.1182/blood-2019-125487

Published: 2019

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

A Cross-Sectional Study of Unmet Needs of Lymphoma Patients in Patient-Doctor Communication: Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Olufunmilayo A Bamigbola, MB;BS, MSc (Epid), Natalie M Dren, BSc, MPH, Lorna E Warwick, BA, B Ed

Blood (2019) 134 (Supplement_1): 4718.

https://doi.org/10.1182/blood-2019-123413

Published: 2019

Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD

Blood (2019) 134 (Supplement_1): 4767.

https://doi.org/10.1182/blood-2019-123688

Published: 2019

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Journal Articles

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Blood (2019) 134 (Supplement_1): 4805.

https://doi.org/10.1182/blood-2019-128743

Published: 2019

Journal Articles

Mental Health Screening in a Pediatric Sickle Cell Disease Clinic: Acceptability and Impact on Mental Health Discussions, Referrals, and Patient Satisfaction

Steven J. Hardy, PhD, Sarah E. Bills, MA, Linda J. Herbert, PhD

Blood (2019) 134 (Supplement_1): 4687.

https://doi.org/10.1182/blood-2019-131875

Published: 2019

Journal Articles

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Emily Molina, DO, MSPH, Gursharon Sanghera, MD, Patrick Hanley, MD, Rafat Ahmed, MD

Blood (2019) 134 (Supplement_1): 4900.

https://doi.org/10.1182/blood-2019-126200

Published: 2019

Journal Articles

Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue): Cognitive Debriefing in Patients with Chronic Lymphocytic Leukemia (CLL)

Helena Chung, MA BA, Daniel Eek, PhD, Calvin Krogh, MBA MPH, Matthew Blowfield, MSc, Oren Meyers, PhD, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 4777.

https://doi.org/10.1182/blood-2019-122849

Published: 2019

Journal Articles

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Pedro de Oliveira Toro da Silva, Cristina Bueno Terzi, MD PhD, Antonio Luis Eiras Falcão, MD PhD, Sara T Olalla Saad, PhD, Fernando Ferreira Costa, MD PhD, Paula De Melo Campos, MD

Blood (2019) 134 (Supplement_1): 4681.

https://doi.org/10.1182/blood-2019-128884

Published: 2019

Journal Articles

Experience with Low Dose Thalidomide in Transfusion Dependent Beta Thalassaemia in a Resource Limited Setting

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Priyanka Soni, MD FNB, Shinto Francis Thekuddan, MBBS,MDDM, Reema Singh, MSc, Vishvdeep Khushoo, MBBS,MDDM, Sumeet Prakash Mirgh, MBBS,MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Jyotsna Kapoor, MSc, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 963.

https://doi.org/10.1182/blood-2019-131682

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

A complementary new drug for PNH

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

A Cross-Sectional Study of Unmet Needs of Lymphoma Patients in Patient-Doctor Communication: Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Mental Health Screening in a Pediatric Sickle Cell Disease Clinic: Acceptability and Impact on Mental Health Discussions, Referrals, and Patient Satisfaction

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue): Cognitive Debriefing in Patients with Chronic Lymphocytic Leukemia (CLL)

Analysis of the Eligibility of Patients with Sickle Cell Disease for Palliative Care

Experience with Low Dose Thalidomide in Transfusion Dependent Beta Thalassaemia in a Resource Limited Setting

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only